The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...
Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...
Git isn’t hard to learn. Moreover, with a Git GUI such as Atlassian’s Sourcetree, and a SaaS code repository such as Bitbucket, mastery of the industry’s most powerful version control tools is within ...
German war-themed metal act Kanonenfieber have dropped their new single "Z-Vor!"" just in time for their early-hours set at Summer Breeze Open Air on Thursday night into Friday morning. The track ...
Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor’s new-look C-suite.
We recently published These 10 Stocks are Winning Big. Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks on Monday. Vor Biopharma extended its winning streak to a fourth consecutive ...
Captain Vor is an iconic villain in Warframe and the first boss you’ll encounter in the game. Before the Isleweaver update, there were only two variants of Vor in the game: Captain Vor and Corrupted ...
Shares of Vor Bio VOR have soared a staggering 265.5% in the past week compared with the industry’s rise of 0.8%. Last week, the company entered a licensing agreement with RemeGen, a China-based ...
Vor Biopharma Inc. (NASDAQ:VOR) saw its stock climb Thursday following a strategic licensing agreement and a major capital raise to support its push into autoimmune therapies. The developments mark a ...
Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...
(RTTNews) - Vor Bio (VOR) and RemeGen Co. announced entry into a license agreement granting Vor Bio global rights excluding China, Hong Kong, Macau and Taiwan to develop and commercialize telitacicept ...
Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions
Less than two months after Vor Bio telegraphed a strategic review, the former cell therapy biotech has made a surprise comeback with a potential $4 billion deal licensing a China-made autoimmune asset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback